Table 2.
Clinical efficacy with abatacept across clinical trials
| Efficacy outcome | MTX-naïve patients |
Patients with inadequate response to MTX |
Patients with inadequate response to anti-TNF agents |
||
|---|---|---|---|---|---|
| AGREE, Year 1 [23] | Phase IIb, Year 1a [38] | AIM, Year 1 [41] | ATTEST, Month 6 [45] | ATTAIN, Month 6 [48] | |
| Abatacept vs placebo | |||||
| ACR20, % | NR | 62.6 vs 36.1 (P < 0.001) | 73.1 vs 39.7 (P < 0.001) | 66.7 vs 41.8 (P < 0.001) | 50.4 vs 19.5 (P < 0.001) |
| ACR50, % | 57.4 vs 42.3 (P < 0.001) | 41.7 vs 20.2 (P < 0.001) | 48.3 vs 18.2 (P < 0.001) | 40.4 vs 20.0 (P < 0.001) | 20.3 vs 3.8 (P < 0.001) |
| ACR70, % | 42.6 vs 27.3 (P < 0.001) | 20.9 vs 7.6 (P = 0.003) | 28.8 vs 6.1 (P < 0.001) | 20.5 vs 9.1 (P = 0.019) | 10.2 vs 1.5 (P = 0.003) |
| LDAS, % | 54.3 vs 36.8 (P < 0.001)b | 49.6 vs 21.9 (P < 0.05) | 42.5 vs 9.9 (P < 0.001) | 20.7 vs 10.8 | 17.1 vs 3.1 (P < 0.001) |
| Remission, % | 41.4 vs 23.3 (P < 0.001) | 34.8 vs 10.1 (P < 0.001) | 23.8 vs 1.9 (P < 0.001) | 11.3 vs 2.9 | 10.0 vs 0.8 (P < 0.001) |
| HAQ-DI response, % | 71.9 vs 62.1 (P = 0.024) | 49.6 vs 27.7 (P < 0.001) | 63.7 vs 39.3 (P < 0.001) | 61.5 vs 40.9 (P = 0.001) | 47.3 vs 23.3 (P < 0.001) |
Data are taken from [23, 39, 42, 46, 49]. aAbatacept data are for the 10 mg/kg group. bData on file; LDAS: DAS-28 ≤3.2; remission: DAS-28 < 2.6; HAQ response: change from baseline in HAQ-DI ≥0.3 U for all trials except for the Phase IIb trial, defined as HAQ-DI mean change from baseline ≥0.22 U; NR: not reported.